跳至主要内容
临床试验/ACTRN12607000109404
ACTRN12607000109404进行中(未招募)不适用

An Antihypertensive Trial to Prevent Stroke with Hydrochlorothiazide combined with Atenolol as required and Nifedipine Sustained Release combined with Captopril as required in patients with hypertension from rural China.

Cardiovascular Institute, Chinese Academy of Medical Sciences0 个研究点目标入组 6,000 人开始时间: 2007年2月7日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
6,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
40 Years 至 75 Years(—)
性别
All

入选标准

  • Hypertensive patients, including untreated hypertensive patients (systolic/diastolic blood pressure >=140/90mmHg at two visits), and treated hypertensive patients (systolic/diastolic blood pressure >=140/90mmHg at two visits).

排除标准

  • Secondary hypertension; controindications to any study drugs; serum potassium values<3.5mEq/L or >5.5mEq/L at screening stage; requirement for any study drugs for reasons other than hypertension; low likelihood of compliance with protocol (eg, dementia, substance abuse); and a history of any severe, life-threatening disease within the past 3 years.

研究者

发起方
Cardiovascular Institute, Chinese Academy of Medical Sciences

相似试验